95 related articles for article (PubMed ID: 16093435)
21. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling.
Waltenberger J; Uecker A; Kroll J; Frank H; Mayr U; Bjorge JD; Fujita D; Gazit A; Hombach V; Levitzki A; Böhmer FD
Circ Res; 1999 Jul; 85(1):12-22. PubMed ID: 10400906
[TBL] [Abstract][Full Text] [Related]
22. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
[TBL] [Abstract][Full Text] [Related]
23. Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells.
Li M; Ping G; Plathow C; Trinh T; Lipson KE; Hauser K; Krempien R; Debus J; Abdollahi A; Huber PE
BMC Cancer; 2006 Mar; 6():79. PubMed ID: 16556328
[TBL] [Abstract][Full Text] [Related]
24. A new tyrosine phosphorylation site in PLC gamma 1: the role of tyrosine 775 in immune receptor signaling.
Serrano CJ; Graham L; DeBell K; Rawat R; Veri MC; Bonvini E; Rellahan BL; Reischl IG
J Immunol; 2005 May; 174(10):6233-7. PubMed ID: 15879121
[TBL] [Abstract][Full Text] [Related]
25. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
Ji QS; Mulvihill MJ; Rosenfeld-Franklin M; Cooke A; Feng L; Mak G; O'Connor M; Yao Y; Pirritt C; Buck E; Eyzaguirre A; Arnold LD; Gibson NW; Pachter JA
Mol Cancer Ther; 2007 Aug; 6(8):2158-67. PubMed ID: 17671083
[TBL] [Abstract][Full Text] [Related]
26. The Potential Targets and Mechanisms of a Carbazole and Pyrazole Containing Anticancer Compound.
Xie J; Gore JC
Curr Cancer Drug Targets; 2020; 20(5):364-371. PubMed ID: 31951182
[TBL] [Abstract][Full Text] [Related]
27. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
28. Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts.
Smith NR; James NH; Oakley I; Wainwright A; Copley C; Kendrew J; Womersley LM; Jürgensmeier JM; Wedge SR; Barry ST
Mol Cancer Ther; 2007 Aug; 6(8):2198-208. PubMed ID: 17699717
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of PDGF-induced phosphoinositide-turnover by glucopiericidin A.
Ahn SC; Kim BY; Park CS; Lee HS; Suh PG; Ryu SH; Rho HM; Rhee JS; Mheen TI; Ahn JS
Biochem Mol Biol Int; 1995 Sep; 37(1):125-32. PubMed ID: 8653074
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic-Pharmacodynamic-Efficacy Modeling of ONO-7579, a Novel Pan-Tropomyosin Receptor Kinase Inhibitor, in a Murine Xenograft Tumor Model.
Iida H; Fujikawa R; Kozaki R; Harada R; Hosokawa Y; Ogawara KI; Ohno T
J Pharmacol Exp Ther; 2020 Jun; 373(3):361-369. PubMed ID: 32217770
[TBL] [Abstract][Full Text] [Related]
31. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
[TBL] [Abstract][Full Text] [Related]
32. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
[TBL] [Abstract][Full Text] [Related]
33. ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action.
Fletcher GC; Brokx RD; Denny TA; Hembrough TA; Plum SM; Fogler WE; Sidor CF; Bray MR
Mol Cancer Ther; 2011 Jan; 10(1):126-37. PubMed ID: 21177375
[TBL] [Abstract][Full Text] [Related]
34. A 120 kDa nuclear phospholipase Cgamma1 protein fragment is stimulated in vivo by EGF signal phosphorylating nuclear membrane EGFR.
Klein C; Gensburger C; Freyermuth S; Nair BC; Labourdette G; Malviya AN
Biochemistry; 2004 Dec; 43(50):15873-83. PubMed ID: 15595842
[TBL] [Abstract][Full Text] [Related]
35. PDGF regulates chondrocyte proliferation through activation of the GIT1- and PLCγ1-mediated ERK1/2 signaling pathway.
Xiao J; Chen X; Xu L; Zhang Y; Yin Q; Wang F
Mol Med Rep; 2014 Nov; 10(5):2409-14. PubMed ID: 25175053
[TBL] [Abstract][Full Text] [Related]
36. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Guo Y; Liu Y; Hu N; Yu D; Zhou C; Shi G; Zhang B; Wei M; Liu J; Luo L; Tang Z; Song H; Guo Y; Liu X; Su D; Zhang S; Song X; Zhou X; Hong Y; Chen S; Cheng Z; Young S; Wei Q; Wang H; Wang Q; Lv L; Wang F; Xu H; Sun H; Xing H; Li N; Zhang W; Wang Z; Liu G; Sun Z; Zhou D; Li W; Liu L; Wang L; Wang Z
J Med Chem; 2019 Sep; 62(17):7923-7940. PubMed ID: 31381333
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
Pietras K; Rubin K; Sjöblom T; Buchdunger E; Sjöquist M; Heldin CH; Ostman A
Cancer Res; 2002 Oct; 62(19):5476-84. PubMed ID: 12359756
[TBL] [Abstract][Full Text] [Related]
38. The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer.
Morishita A; Gong J; Nomura T; Yoshida H; Izuishi K; Suzuki Y; Kushida Y; Haba R; D'Armiento J; Masaki T
Int J Oncol; 2010 Oct; 37(4):829-35. PubMed ID: 20811704
[TBL] [Abstract][Full Text] [Related]
39. Structure-activity studies on a library of potent calix[4]arene-based PDGF antagonists that inhibit PDGF-stimulated PDGFR tyrosine phosphorylation.
Zhou H; Wang DA; Baldini L; Ennis E; Jain R; Carie A; Sebti SM; Hamilton AD
Org Biomol Chem; 2006 Jun; 4(12):2376-86. PubMed ID: 16763682
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylation of PLCγ1 by EphA2 Receptor Tyrosine Kinase Promotes Tumor Growth in Lung Cancer.
Song W; Kim LC; Han W; Hou Y; Edwards DN; Wang S; Blackwell TS; Cheng F; Brantley-Sieders DM; Chen J
Mol Cancer Res; 2020 Nov; 18(11):1735-1743. PubMed ID: 32753469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]